Last reviewed · How we verify
NCT06709378
Effectiveness and Safety of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus
trial in Dislocated Lens in 9 participants. Completed in 1 September 2024.
1 September 2024
Quick facts
| Lead sponsor | Changzhou No.2 People's Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 9 |
| Start date | 1 July 2022 |
| Primary completion | 1 September 2024 |
| Estimated completion | 1 September 2024 |
| Sites | 1 location across China |
Conditions studied
- Dislocated Lens — all drugs for Dislocated Lens →
- Pars Plana Vitrectomy — all drugs for Pars Plana Vitrectomy →
- Phacoemulsification — all drugs for Phacoemulsification →
- Needle — all drugs for Needle →
Sponsor
Changzhou No.2 People's Hospital
Who can join
Eligibility, any sex, with Dislocated Lens or Pars Plana Vitrectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about the effects of 25-gauge (G) needle-assisted phacoemulsification to remove dislocated intravitreal lens nuclei.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus.
Feng Q, Li Y, Jiang Y, Sun X. · · 2026 · PMID 42211675 · DOI 10.1155/joph/8429779
Verify or expand the search:
- PubMed search for NCT06709378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Changzhou No.2 People's Hospital trials
Trials by the same sponsor.
- NCT06337474 — An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia · EARLY_PHASE1 · recruiting
- NCT06404281 — γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors · Phase 1 · recruiting
- NCT06403111 — FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC · Phase 2 · recruiting
- NCT06405113 — FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer · Phase 2 · recruiting
- NCT06379451 — An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06709378 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changzhou No.2 People's Hospital
- Last refreshed: 29 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06709378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing